PMID- 35433433
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220512
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - Harnessing the Anti-Tumor Mediators in Mast Cells as a New Strategy for Adoptive 
      Cell Transfer for Cancer.
PG  - 830199
LID - 10.3389/fonc.2022.830199 [doi]
LID - 830199
AB  - The emergence of cancer immunotherapies utilizing adoptive cell transfer (ACT) 
      continues to be one of the most promising strategies for cancer treatment. Mast 
      cells (MCs) which occur throughout vascularized tissues, are most commonly 
      associated with Type I hypersensitivity, bind immunoglobin E (IgE) with high 
      affinity, produce anti-cancer mediators such as tumor necrosis factor alpha 
      (TNF-alpha) and granulocyte macrophage colony-stimulating factor (GM-CSF), and 
      generally populate the tumor microenvironments. Yet, the role of MCs in cancer 
      pathologies remains controversial with evidence for both anti-tumor and pro-tumor 
      effects. Here, we review the studies examining the role of MCs in multiple forms 
      of cancer, provide an alternative, MC-based hypothesis underlying the mechanism 
      of therapeutic tumor IgE efficacy in clinical trials, and propose a novel 
      strategy for using tumor-targeted, IgE-sensitized MCs as a platform for 
      developing new cellular cancer immunotherapies. This autologous MC cancer 
      immunotherapy could have several advantages over current cell-based cancer 
      immunotherapies and provide new mechanistic strategies for cancer therapeutics 
      alone or in combination with current approaches.
CI  - Copyright (c) 2022 Fereydouni, Motaghed, Ahani, Kafri, Dellinger, Metcalfe and 
      Kepley.
FAU - Fereydouni, Mohammad
AU  - Fereydouni M
AD  - Department of Nanoscience, Joint School of Nanoscience and Nanoengineering, 
      University of North Carolina Greensboro (UNCG), Greensboro, NC, United States.
FAU - Motaghed, Mona
AU  - Motaghed M
AD  - Department of Nanoengineering, Joint School of Nanoscience and Nanoengineering, 
      North Carolina A&T State University, Greensboro, NC, United States.
FAU - Ahani, Elnaz
AU  - Ahani E
AD  - Department of Nanoengineering, Joint School of Nanoscience and Nanoengineering, 
      North Carolina A&T State University, Greensboro, NC, United States.
FAU - Kafri, Tal
AU  - Kafri T
AD  - Gene Therapy Center and Department of Microbiology and Immunology, University of 
      North Carolina at Chapel Hill, Chapel Hill, NC, United States.
FAU - Dellinger, Kristen
AU  - Dellinger K
AD  - Department of Nanoengineering, Joint School of Nanoscience and Nanoengineering, 
      North Carolina A&T State University, Greensboro, NC, United States.
FAU - Metcalfe, Dean D
AU  - Metcalfe DD
AD  - Laboratory of Allergic Diseases, National Institute of Allergy and Infectious 
      Diseases, National Institutes of Health, Bethesda, MD, United States.
FAU - Kepley, Christopher L
AU  - Kepley CL
AD  - Department of Molecular and Cellular Sciences, Liberty University College of 
      Osteopathic Medicine, Lynchburg, VA, United States.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220331
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9009255
OTO - NOTNLM
OT  - FcepsilonRI
OT  - IgE
OT  - adoptive cell transfer
OT  - cancer immunotherapy
OT  - mast cells
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/04/19 06:00
MHDA- 2022/04/19 06:01
PMCR- 2022/01/01
CRDT- 2022/04/18 06:38
PHST- 2021/12/06 00:00 [received]
PHST- 2022/02/28 00:00 [accepted]
PHST- 2022/04/18 06:38 [entrez]
PHST- 2022/04/19 06:00 [pubmed]
PHST- 2022/04/19 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.830199 [doi]
PST - epublish
SO  - Front Oncol. 2022 Mar 31;12:830199. doi: 10.3389/fonc.2022.830199. eCollection 
      2022.